ADVA
27.4.2021 09:02:12 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5405-MB , the industry’s first ultra-compact outdoor PTP grandmaster clock with multi-band GNSS receiver and integrated antenna. Part of the OSA 5405 Series of smart synchronization devices for indoor or outdoor deployment, the OSA 5405-MB ensures timing accuracy by eliminating the impact of ionospheric delay variation. This empowers communication service providers (CSPs) and enterprises to deliver the nanosecond precision needed for 5G fronthaul and other emerging time-sensitive applications. The multi-band GNSS receiver and integrated antenna enable the OSA 5405-MB to meet PRTC-B accuracy requirements (+/-40nsec) even in challenging conditions. For the first time, the technology is available in an edge timing device with minimal footprint, helping operators achieve unprecedented accuracy and reliability as they roll out wide-spread small cell networks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005060/en/
“Our multi-band, multi-constellation GNSS receiver provides an extremely cost-efficient way to achieve PRTC-B UTC-traceable network timing with the levels of accuracy needed for next-generation use cases. By adding this technology to our versatile, small-form-factor OSA 5405 Series, we’re offering a route to precision synchronization at the network access without significant investment,” said Gil Biran, general manager, Oscilloquartz, ADVA. “A ruggedized design and minimal visibility make our OSA 5405-MB easy to install in almost any outdoor location. With the power to compensate for ionospheric delay variations and provide resilience against jamming and spoofing, our compact edge solution really is the key to 5G synchronization.”
The OSA 5405 Series is a uniquely versatile timing solution ideal for deployment deep in urban canyons, precisely where the most advanced end applications require stringent synchronization. With its small form factor, the OSA 5405-I indoor variant can be positioned on windows to avoid multipath signal interference. Offering both electrical and optical interfaces and featuring cost-effective Ethernet cabling, the OSA 5405 Series avoids the archaic and expensive RF feeds of traditional GNSS installations by integrating an antenna, GNSS receiver and PTP grandmaster in a single device.
Now with multi-band GNSS technology, the OSA 5405-MB also protects against timing inaccuracies caused by ionospheric disturbance. By receiving GNSS signals in two frequency bands and using the differences between them to calculate and compensate for delay variation, the OSA 5405-MB eliminates inaccuracy and ensures ultra-precise synchronization whatever the space weather conditions. It can also work with up to four concurrent GNSS constellations (GPS, GALILEO, GLONASS and BEIDOU), increasing the number of observable satellites in urban canyons. A comprehensive set of Syncjack™ PTP and GNSS jamming and spoofing monitoring features in combination with ADVA’s Ensemble Controller and Sync Director assures highest synchronization quality and provides transparency for simple operation of even very large synchronization networks. The OSA 5405-MB also offers network-delivered timing backup to further mitigate GNSS vulnerabilities and make synchronization more robust and resilient.
“Highly accurate timing is becoming more critical every year. In CSP infrastructure, power utilities, broadcast and enterprise networks across most industries, precision synchronization that meets tight PRTC-B specifications is essential. The OSA 5405-MB is capable of providing different PTP profiles as well as NTP directly out of the smart antenna with no compromise on accuracy,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “With its multi-band receiver, our new OSA 5405-MB delivers PRTC-B levels of synchronization accuracy. Small, lightweight, low-power and versatile, it can be deployed almost anywhere and will perform perfectly even under extreme conditions. What’s more, its Syncjack™ PTP and GNSS assurance capabilities ensure accurate, real-time monitoring of timing quality.”
Further information on the OSA 5405-MB is available in these slides: https://adva.li/osa-5405-mb-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005060/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
